Clinical Trial Update: A Study of SEA-CD40 Given With Other Drugs in Cancers [Phase 2]

View source ↗

Summary

Phase 2 study of SEA-CD40 in combination with other therapies for melanoma and non-small cell lung cancer has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• SEA-CD40

Snippet

Sponsor: Seagen Inc. | Conditions: Melanoma, Carcinoma, Non-Small- Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2025-01-22